A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07

Trial Profile

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Duvelisib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 20 Jun 2014 Planned End Date changed from 1 Dec 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 20 Jun 2014 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2018 as reported by ClinicalTrials.gov record.
    • 31 May 2014 Planned number of patients changed from 150 to 307 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top